“Commentary:Of China’s 1.4b population, lung disease is a major public health problem responsible for approximately 1m deaths p.a. or 10% of all deaths, while approximately ~210m (15%) suffer from COPD, while ~40m people (3%) suffer from asthma. Asthma, COPD, air pollution, and smoking are the main causes of chronic respiratory diseases. COVID is an essentially pulmonary disease and the long-term incidence of pulmonary fibrosis is uncertain and likely to vary between different COVID variants, but many survivors may require chronic home monitoring of lung function to ensure no progress of Long COVID complications.Executive Chairman of Uscom, Professor Rob Phillips said “The NMPA acceptance of our SpiroSonic technologies in China is a significant commercial leap for Uscom into the most populous medical and medical consumer market in the world, and Uscom looks forward to activating our expanding sales teams to convert this opportunity into revenue. The SpiroSonic world leading technology provides research grade monitoring in a digital environment with an easy to use and disinfect technology suited to clinical and eHealth environments.”The size and scale of the new manufacturing arrangements allow for concurrent manufacture of multiple products, for multiple markets and can accommodate expanded device manufacture volume as required. Products with existing regulatory approval will be given manufacturing priority.”
UCM Price at posting:
6.5¢ Sentiment: None Disclosure: Held
